Stephen V Liu: Long-term survival with nivolumab and ipilimumab in advanced NSCLC

Stephen V Liu shared on X:

“Long-term survival (median f/u 73.7m) with nivolumab and ipilimumab (+/- chemo, CheckMate 9LA and 227) in advanced NSCLC with PD-L1 <1% Journal of Thoracic Oncology. Significant OS benefit including pts with brain mets (HR 0.44) and squamous (HR 0.51). mDOR 18 vs 4.6m.”

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis

Authors: Solange Peters,  Luis G. Paz-Ares, Martin Reck, David P. Carbone, Julie R. Brahmer, Hossein Borghaei, Shun Lu, Kenneth J. O’Byrne, Thomas John, Tudor-Eliade Ciuleanu, Michael Schenker, Reyes Bernabe Caro, Makoto Nishio, Manuel Cobo, Jong-Seok Lee, Bogdan Zurawski,Adam Pluzanski, Takekazu Aoyama, Marina Tschaika, Vipul Devas, Diederik J. Grootendorst, Suresh S. Ramalingam,

More posts featuring Stephen V Liu on oncodaily.com

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.